Are you ready for the next big shift in biosimilar development?  The biosimilar landscape is evolving at lightning speed, driven by groundbreaking regulatory updates from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The EMA’s 2025 reflection paper introduces a tailored clinical approach that promises to streamline biosimilar development, while...

The recent American Society of Clinical Oncology (ASCO) conference served as a platform for Accelsiors to showcase our expertise, forge valuable connections, and reinforce our commitment to advancing cancer care and saving lives. The conference also provided opportunities for us to share our latest technological achievements and demonstrate our commitment to staying at the forefront...

We are happy to announce that the first two patients have been successfully randomized in the Phase 2 portion of the clinical trial evaluating golexanolone for the treatment of cognitive symptoms in Primary Biliary Cholangitis (PBC). This randomized, double-blind, placebo-controlled study aims to assess the efficacy of golexanolone in improving cognitive function, fatigue, and daytime...

We’re still under the impact of Bio Korea 2024. This prestigious event brought together leading minds and organizations in biotechnology from around the world to discuss the future of innovation and global collaboration in the field.   One of the key highlights was the “Smart Clinical Trial” session on the opening day, which focused on...

Accelsiors is pleased to present the key highlights of our participation in the highly anticipated Swiss Biotech Day 2024, which took place on April 22-23 at the Congress Center Basel in Switzerland. This event is renowned as one of Europe’s leading biotechnology conferences, serving as a crucial platform for industry professionals to connect, share ideas,...

We are thrilled about our participation at the Pharmabiotics Conference & Partnering 2024. The event took place in Lille, France, marking the 9th edition of this prestigious conference. As a member of the Board of Directors of the Pharmabiotic Research Institute (PRI), Accelsiors played a crucial role in fostering collaboration and knowledge sharing within the...

Accelsiors continues to support ADPD, with our attendance at this year’s conference in Lisbon, in March 2024! ADPD 2024, brought together esteemed colleagues, investigators, and partners from around the world. The conference provided a platform for experts to showcase groundbreaking research, discuss recent challenges, and explore innovative solutions in the fields of Alzheimer’s and Parkinson’s...